Vivus

Vivus’ Qsymia beats out weight loss competitors in pricing watchdog's latest cost-effectiveness analysis
Endpoints
Wed, 07/13/22 - 08:22 pm
Vivus
Qsymia
weight loss
ICER
Novo Nordisk
Saxenda
Wegovy
A decade after its first approval, FDA expands weight loss pill's label for use in adolescents
Endpoints
Tue, 06/28/22 - 10:44 am
Vivus
Qsymia
teens
FDA
obesity
Acceleron’s post-Reblozyl plan comes together
EP Vantage
Tue, 01/28/20 - 11:09 am
Acceleron
sotatercept
PAH
JNJ
Bellerophon Therapeutics
United Therapeutics
Vivus
Arena
Novartis
Vivus, diving into the cystic fibrosis sphere, backs stadium step-climbing fundraiser
Fierce Pharma
Thu, 09/27/18 - 11:58 am
Vivus
cystic fibrosis
Pancreaze
Moving Beyond Obesity, Vivus Strikes $135M Deal for Digestive Drug
Xconomy
Tue, 05/1/18 - 09:54 pm
Vivus
Qsymia
Pancreaze
Janssen
Vivus Inc. stock rises 4.6% after regaining certain commercial rights for Stendra from Sanofi
Marketwatch
Mon, 03/27/17 - 09:52 am
Vivus
Stendra
Sanofi
erectile dysfunction
Vivus reports 3Q loss
Yahoo/AP
Thu, 11/10/16 - 11:00 am
Vivus
earnings
Post-Endo pact, will Vivus go it alone on U.S. Stendra marketing--and should it?
Fierce Pharma
Sat, 08/6/16 - 01:03 pm
Vivus
Stendra
erectile dysfunction
Endo
Vivus Announces Positive Ruling In Qsymia Litigation - Will It Matter?
Seeking Alpha
Sat, 07/23/16 - 09:58 am
Vivus
Qsymia
obesity
Vivus: Qsymia Sales Close Out Q2 With Worst Sales Volume In 2 Years
Seeking Alpha
Mon, 07/11/16 - 09:12 am
Vivus
Qsymia
obesity
Vivus - Qsymia Sales Still Trending In The Wrong Direction
Seeking Alpha
Tue, 06/21/16 - 11:19 am
Vivus
Qsymia
obesity
Orexigen struggles to stay afloat as obesity market stagnates
BioPharma Dive
Thu, 05/19/16 - 09:43 am
Orexigen
obesity
Contrave
Vivus
Qsymia
Takeda
Arena Investors: What To Consider As Anti-Obesity Drugs Fizzle
Seeking Alpha
Mon, 05/16/16 - 09:32 pm
Arena Pharmaceuticals
obesity
Orexigen
Belviq
Eisai
Vivus
Novo Nordisk
Qsymia
Victoza
Orexigen: Contrave Sales Flatten Out At End Of Q1
Seeking Alpha
Mon, 04/11/16 - 09:58 am
Orexigen
Contrave
obesity
Novo Nordisk
Vivus
Arena Pharmaceuticals
Vivus posts 4th-quarter loss of $12.2 million
Yahoo/AP
Thu, 03/10/16 - 09:58 am
Vivus
earnings
Hoping Vivus and Orexigen can finally kick-start their obesity meds? Don't count on it, analyst says
Fierce Pharma Marketing
Tue, 03/1/16 - 10:56 pm
obesity
Vivus
Orexigen
Contrave
Qsymia
Takeda
Vivus- Were Qsymia Patents Strong Enough? Actavis Stance Questions That
Seeking Alpha
Fri, 02/26/16 - 10:26 pm
Vivus
Qsymia
patents
Actavis
Belviq Sales Close Out 2015 With A Slump
Seeking Alpha
Sat, 01/9/16 - 10:39 am
Belviq
Arena Pharmaceuticals
obesity
Vivus
Orexigen
Endo opts of licensing deal for ED drug
Bizjournals.com
Fri, 01/1/16 - 11:46 am
Endo International
Stendra
Vivus
erectile dysfunction
Vivus reports 3Q loss
Yahoo/AP
Thu, 11/5/15 - 09:32 am
Vivus
earnings

Pages